IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
IDEAYA Biosciences, a precision medicine oncology company, announced its participation in two upcoming investor relations events in June 2024. The company will be represented by CEO Yujiro S. Hata at the Jefferies Global Healthcare Conference on June 5th, 2024, at 9:00 AM ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10th, 2024, at 8:00 AM ET. Both events will feature fireside chats hosted by equity research analysts. Live audio webcasts of these events will be available on the IDEAYA website, with replays accessible for 30 days after the events.
- IDEAYA Biosciences is participating in high-profile investor conferences, signaling active engagement with the investment community.
- CEO Yujiro S. Hata will represent the company, potentially increasing investor confidence and interest.
- Live audio webcasts will expand the reach of the presentations, allowing broader access to the company's strategic insights.
- No new financial data or clinical trial updates are provided in this announcement, which might be seen as a lack of significant news.
- The impact of these events on the stock price of IDYA is uncertain, as participation alone does not guarantee positive investor reaction.
2024 Jefferies Global Healthcare Conference
Wednesday, June 5th, 2024 at 9:00 AM ET
- Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology
Goldman Sachs 45th Annual Global Healthcare Conference
Monday, June 10th, 2024 at 8:00 AM ET
- Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Corinne (Jenkins) Johnson, Vice President, Equity Research, Biotechnology
A live audio webcast of the conference events, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-june-2024-investor-relations-events-302155550.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What events will IDEAYA Biosciences participate in June 2024?
Who will represent IDEAYA Biosciences at the June 2024 conferences?
Will the IDEAYA Biosciences presentations be available online?
What is the stock symbol for IDEAYA Biosciences?
